Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB41 in advanced malignant solid tumours
NCT06600022Phase 2Recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Oct 2024
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SCTB41 in advanced malignant solid tumor, sponsored by Sinocelltech Group Limited. Primary endpoints: Dose-Limiting Toxicity and Objective Response Rate up to 2 years. Started Oct 2024; status: recruiting.
02
Drugs
SCTB41
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT06600022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06600022.